Enrolment for Phase 3 study of MTBVAC in newborns completed
We are proud to announce the completion of enrolment in the Phase 3 clinical trial evaluating MTBVAC in 7,120 newborns in sub-Saharan Africa – an important milestone in the development of a new vaccine against tuberculosis (TB). TB remains one of the world’s deadliest infectious diseases, causing an estimated 10.8 million new cases and 1.25 […]